Table 2. Association between PD-L1 expression and clinico-pathological characteristics.
| Parameter | PDL-1 expression | |||
|---|---|---|---|---|
| Low (%) | High (%) | p-value | ||
| Age at diagnosis (yrs) | ≤35 years | 8 (62%) | 5 (38%) | 0.046 |
| >35 years | 362 (84%) | 68 (16%) | ||
| Tumor size (cm) | T1a/b | 1 (50%) | 1 (50%) | 0.629 |
| T1c | 57 (83%) | 12 (17%) | ||
| T2 | 231 (83%) | 46 (17%) | ||
| T3 | 56 (85%) | 10 (15%) | ||
| Nodal status | Positive | 193 (85%) | 35 (15%) | 0.980 |
| Negative | 161 (85%) | 29 (15%) | ||
| Tumor grade | 1 | 62 (87%) | 9 (13%) | 0.001 |
| 2 | 233 (87%) | 34 (13%) | ||
| 3 | 73 (71%) | 30 (29%) | ||
| ER status | Positive | 212 (88%) | 28 (12%) | 0.005 |
| Negative | 158 (78%) | 45 (22%) | ||
| PR status | Positive | 192 (89%) | 23 (11%) | 0.002 |
| Negative | 178 (78%) | 50 (22%) | ||
| Molecular subtypes | Luminal A | 170 (88%) | 23 (12%) | 0.013 |
| Luminal B | 38 (79%) | 10 (21%) | ||
| Her2 | 61 (91%) | 6 (9%) | ||
| TNNBa | 24 (69%) | 11 (31%) | ||
| Basal-like | 46 (67%) | 23 (33%) | ||
aTNNB: Triple negative non-basal.